

Roy van der Meel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3449137/publications.pdf>

Version: 2024-02-01

46
papers

6,670
citations

159585

30
h-index

214800

47
g-index

48
all docs

48
docs citations

48
times ranked

8650
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. <i>Journal of Controlled Release</i> , 2022, 349, 174-183.	9.9	10
2	A modular approach toward producing nanotherapeutics targeting the innate immune system. <i>Science Advances</i> , 2021, 7, .	10.3	20
3	Prosaposin mediates inflammation in atherosclerosis. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	42
4	The current landscape of nucleic acid therapeutics. <i>Nature Nanotechnology</i> , 2021, 16, 630-643.	31.5	578
5	Nanoengineering Apolipoprotein A1-Based Immunotherapeutics. <i>Advanced Therapeutics</i> , 2021, 4, 2100083.	3.2	8
6	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. <i>Small</i> , 2021, 17, e2103025.	10.0	29
7	Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach. <i>Langmuir</i> , 2021, 37, 1120-1128.	3.5	50
8	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021, 32, 012001.	2.6	17
9	Nuclear imaging approaches facilitating nanomedicine translation. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 123-141.	13.7	41
10	Dexamethasone nanomedicines for COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 622-624.	31.5	138
11	Cancer nanomedicine meets immunotherapy: opportunities and challenges. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 954-958.	6.1	33
12	Nanotechnology for organ-tunable gene editing. <i>Nature Nanotechnology</i> , 2020, 15, 253-255.	31.5	16
13	The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. <i>Theranostics</i> , 2020, 10, 7921-7924.	10.0	459
14	Lipid nanoparticle technology for therapeutic gene regulation in the liver. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 344-363.	13.7	187
15	Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency. <i>Blood</i> , 2020, 136, 2946-2954.	1.4	17
16	Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. <i>Accounts of Chemical Research</i> , 2019, 52, 2435-2444.	15.6	270
17	Smart cancer nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 1007-1017.	31.5	776
18	Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. <i>Nanoscale</i> , 2019, 11, 9023-9031.	5.6	85

#	ARTICLE	IF	CITATIONS
19	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. <i>Nature Nanotechnology</i> , 2019, 14, 1084-1087.	31.5	814
20	Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 146-157.	3.6	335
21	On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. <i>ACS Nano</i> , 2018, 12, 4787-4795.	14.6	319
22	State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery. <i>Small Methods</i> , 2018, 2, 1700375.	8.6	165
23	Translating nanomedicines: Thinking beyond materials? A young investigator's reply to "The Novelty Bubble". <i>Journal of Controlled Release</i> , 2018, 290, 138-140.	9.9	12
24	In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System. <i>Molecular Pharmaceutics</i> , 2017, 14, 1681-1690.	4.6	18
25	Cancer nanomedicines: oversold or underappreciated?. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1-5.	5.0	107
26	Cetuximab treatment alters the content of extracellular vesicles released from tumor cells. <i>Nanomedicine</i> , 2016, 11, 881-890.	3.3	20
27	The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. <i>Molecular Therapy</i> , 2016, 24, 2100-2108.	8.2	38
28	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. <i>Journal of Controlled Release</i> , 2016, 224, 77-85.	9.9	402
29	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. <i>Fundamental Biomedical Technologies</i> , 2016, , 163-200.	0.2	16
30	An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 74, 103-117.	4.0	40
31	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Stacking Stabilized Polymeric Micelles. <i>ACS Nano</i> , 2015, 9, 3740-3752.	14.6	185
32	Capillary electrophoresis-based assessment of nanobody affinity and purity. <i>Analytica Chimica Acta</i> , 2014, 818, 1-6.	5.4	17
33	Extracellular vesicles as drug delivery systems: Lessons from the liposome field. <i>Journal of Controlled Release</i> , 2014, 195, 72-85.	9.9	372
34	Toward routine detection of extracellular vesicles in clinical samples. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 244-253.	1.3	56
35	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. <i>Molecular Pharmaceutics</i> , 2013, 10, 3717-3727.	4.6	26
36	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1284-1298.	13.7	338

#	ARTICLE	IF	CITATIONS
37	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. <i>Journal of Controlled Release</i> , 2013, 165, 110-118.	9.9	88
38	Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. <i>Journal of Controlled Release</i> , 2012, 160, 211-216.	9.9	33
39	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. <i>Journal of Controlled Release</i> , 2012, 159, 281-289.	9.9	83
40	Nanobody "Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. <i>Journal of Controlled Release</i> , 2011, 151, 183-192.	9.9	94
41	Reprint of "Nanobody "Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". <i>Journal of Controlled Release</i> , 2011, 153, 93-102.	9.9	29
42	The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. <i>Drug Discovery Today</i> , 2011, 16, 219-228.	6.4	65
43	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. <i>Angiogenesis</i> , 2011, 14, 457-466.	7.2	37
44	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. <i>Journal of Controlled Release</i> , 2010, 145, 165-175.	9.9	117
45	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. <i>Drug Discovery Today</i> , 2010, 15, 102-114.	6.4	45
46	Controlling Cardiomyocyte Survival. <i>Novartis Foundation Symposium</i> , 2008, , 41-57.	1.1	12